Who are FULVICIN P/G 330's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): GRIFULVIN V, GRISEOFULVIN, GRISACTIN ULTRA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/griseofulvin-ultramicrosize.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

FULVICIN P/G 330 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FULVICIN P/G 330 (GRISEOFULVIN, ULTRAMICROSIZE) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Dermatology.

marketed Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin Dermatology Live · refreshed every 30 min

Target snapshot

FULVICIN P/G 330 (GRISEOFULVIN, ULTRAMICROSIZE) — CHARTWELL RX.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FULVICIN P/G 330 TARGET	GRISEOFULVIN, ULTRAMICROSIZE	CHARTWELL RX	marketed		Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin
GRIFULVIN V	GRISEOFULVIN, MICROCRYSTALLINE	JOHNSON AND JOHNSON	marketed		Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin
GRISEOFULVIN	GRISEOFULVIN, MICROSIZE	COSETTE	marketed	Tubulin Inhibiting Agent [EPC]	Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin
GRISACTIN ULTRA	GRISEOFULVIN, ULTRAMICROCRYSTALLINE	WYETH AYERST	marketed		Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FULVICIN P/G 330 — Competitive Intelligence Brief. https://druglandscape.com/ci/griseofulvin-ultramicrosize. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing